EDIT

Editas Medicine EDIT incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter. Collaboration and other research and development revenues totaled approximately $11.9 million, comfortably surpassing the Zacks Consensus Estimate of $2 million. Revenues were $3.6 million in the year-ago quarter. The increase reflected deferred revenues recognized following the expiration of certain rights under the company’s collaboration with Bristol Myers. Research and development expenses increased 25% year over year to $20.2 million in the second quarter of 2026. The increase was primarily related to higher external expenses supporting ongoing research and preclinical work for EDIT-401. General and administrative expenses declined 10% to $11.6 million from $12.9 million in the year-ago quarter. The decrease was due to lower employee-related expenses and reduced professional services costs following the workforce reduction and discontinuation of the reni-cel program. Editas recorded a restructuring and impairment benefit of $1.3 million in the reported quarter. This compared favorably with restructuring and impairment charges of $26.1 million in the second quarter of 2025. The benefit reflected favorable adjustments to previously estimated contract costs associated with the discontinuation of the reni-cel program. Editas had cash, cash equivalents and investments worth $211.6 million as of June 30, 2026, compared with $123.6 million as of March 31, 2026. The company expects its existing cash position to fund operating and capital needs into the second half of 2028. Year to date, shares of Editas have soared 34.1% compared with the industry’s 2.5% growth. Image Source: Zacks Investment Research Editas has no approved products in its portfolio at present. Therefore, progress with its gene-editing pipeline, particularly lead candidate EDIT-401, remains the company’s primary focus. EDIT-401 is an experimental, one-time in vivo gene-editing therapy targeting the LDLR gene. The candidate is being developed for patients with heterozygous familial hypercholesterolemia, an inherited disorder associated with elevated LDL cholesterol and increased cardiovascular risk. Editas presented new preclinical findings for EDIT-401 at several scientific conferences. A single dose of the candidate produced mean reductions of approximately 90% or more in LDL cholesterol, lipoprotein(a) and apolipoprotein B in non-human primates. The reductions were rapid and dose-dependent. A mean LDL cholesterol reduction of at least 90% remained durable for approximately six months. The company also reported no adverse clinical observations in non-human primates receiving a single dose of 1.5 milligrams per kilogram. Editas remains on track to submit a Clinical Trial Notification in Australia in August 2026. The filing is intended to support the initiation of a phase I/II study evaluating EDIT-401 in patients with heterozygous familial hypercholesterolemia. The study will assess the safety, tolerability and efficacy of a single dose of EDIT-401. Its first part will use a single ascending dose, open-label design. Editas has selected four clinical study sites across Australia and New Zealand. The company expects to provide an EDIT-401 data update in the first quarter of 2027. It also plans to complete enrollment in the dose-finding portion of the phase I/II study and report top-line results in 2027. Editas Medicine, Inc. price-consensus-eps-surprise-chart | Editas Medicine, Inc. Quote Editas currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY, Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have gained 2.2% year to date. Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters and beat on the remaining occasion, delivering an average negative surprise of 13.97%. Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 3.2% year to date. Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%. Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 158.4% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report Repligen Corporation (RGEN) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates Recent financing strengthens Company’s capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the second quarter 2026 and provided business updates. “During the second quarter, we continued preclinical work to support advancing EDIT-401 into a single ascending dose, open-label Phase 1/2 study,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We also presented new preclinical data demonstrating the ability of a single dose of EDIT-401 to achieve rapid and significant reductions in multiple atherogenic lipoproteins in non-human primates along with a promising preclinical safety profile, reinforcing EDIT-401’s potential as a best-in-class, one-time treatment for hyperlipidemia. In addition, with our recent equity financing, we are well capitalized to drive the clinical development of EDIT-401 through key value-creating milestones. We look forward to our continued progress and expect to provide a data update in the first quarter of 2027.” EDIT-401 Editas presented new EDIT-401 preclinical data at the 94th European Atherosclerosis Society (EAS) Congress, the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), and TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, including: Editas is on track to submit a Clinical Trial Notification (CTN) in Australia this month and continues to progress towards initiating a Phase 1/2 clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH). Corporate & Business Development Updates In May, Editas completed a public offering of common stock and accompanying common stock warrants. The aggregate gross proceeds from the offering were $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, if all common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses. Editas announced the appointment of Patrick T. Ellinor, M.D., Ph.D. to its Board of Directors. Dr. Ellinor is a recognized leader in cardiovascular medicine and human genetics and brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership to Editas. Second Quarter 2026 Financial ResultsCash and cash equivalents as of June 30, 2026, were $211.6 million compared to $146.6 million as of December 31, 2025. The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2028. Second Quarter 2026 For the three months ended June 30, 2026, net loss attributable to common stockholders was $18.2 million, or $0.15 per share, compared to net loss of $53.2 million, or $0.63 per share, for the same period in 2025. Collaboration and other research and development revenues increased to $11.9 million for the three months ended June 30, 2026, compared to $3.6 million for the same period in 2025. The increase was primarily attributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additional research programs under its collaboration with BMS. Research and development expenses increased by $4.0 million to $20.2 million for the three months ended June 30, 2026, compared to $16.2 million for the same period in 2025. The decrease is primarily related to increased external expenses for ongoing research and preclinical efforts for EDIT-401. General and administrative expenses decreased by $1.3 million to $11.6 million for the three months ended June 30, 2026 compared to $12.9 million for the same period in 2025. The decrease is primarily attributable to a reduction in employee-related expenses, as well as reduced professional services, in connection with the reduction in headcount (the “Reduction”) and discontinuation of the clinical development of the Company’s reni-cel program (the “Discontinuation”) initiated in December 2024 and ongoing throughout 2025. Restructuring and impairment charges decreased by $27.4 million to a $1.3 million benefit for the three months ended June 30, 2026 compared to $26.1 million for the same period in 2025. The decrease is primarily attributable to favorable adjustments to prior estimated costs for contracts associated with the Discontinuation upon finalization of contract costs. About Heterozygous Familial Hypercholesterolemia (HeFH) Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population. About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to complete enrolling the dose-finding portion of the planned Phase 1/2 clinical trial of EDIT-401 with topline data results available in 2027; the timing for the Company’s receipt and presentation of data from its preclinical and planned clinical studies, including providing a data update on EDIT-401 in the first quarter of 2027; the potential of, and expectations for, EDIT-401; the timing or likelihood of regulatory submissions and approvals, including submission of a CTN in Australia this month; and the Company’s expectations regarding its cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated on the expected timelines or at all; and uncertainties as to whether the Company’s cash resources are sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements for the period anticipated. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. CONTACT: Investor and Media Contacts: [email protected] [email protected]

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 12.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Editasincurred a loss of 26 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 43 cents per share in the year-ago quarter. Loss narrowed year over year, primarily driven by lower operating expenses. Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, totaled $2.8 million in the reported quarter, down 39.2% from the year-ago quarter’s figure. The reported figure fell short of the Zacks Consensus Estimate of $9 million. The year-over-year decrease was primarily due to the recognition of revenues related to milestones achieved under EDIT’s collaboration agreement with a strategic partner in 2025. In the first quarter of 2026, R&D expenses decreased 34% to $17.6 million compared with $26.6 million reported in the year-ago period. The decline was primarily driven by lower headcount and reduced clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by in vivo research and discovery costs. General and administrative expenses were $10.2 million in the reported quarter, down 23.5% year over year, due to a decline in employee-related expenses resulting from a reduced workforce and lower professional service expenses following the abandonment of the reni-cel program. Editas did not record any restructuring and impairment charges in the first quarter of 2026 compared with $40.9 million in the year-ago quarter. Editas had cash, cash equivalents and investments worth $123.6 million as of March 31, 2026, compared with $146.6 million as of Dec. 31, 2025. The company expects its existing cash position to fund operating and capital needs into the third quarter of 2027. Since the earnings release, investors have witnessed a upward trend in fresh estimates. At this time, Editas has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the fifth quintile for value investors. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Editas belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Illumina (ILMN), has gained 19.9% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026. Illumina reported revenues of $1.09 billion in the last reported quarter, representing a year-over-year change of +4.8%. EPS of $1.15 for the same period compares with $0.97 a year ago. For the current quarter, Illumina is expected to post earnings of $1.24 per share, indicating a change of +4.2% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. Illumina has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data at upcoming scientific meetings, including data showing significant reductions in Lp(a) and ApoB in non-human primates at the 94th EAS Congress U.S. Patent and Trademark Office reaffirmed prior decision in favor of the Broad Institute in CRISPR/Cas9 interference CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2026 and provided business updates. “In the first quarter, we continued to advance EDIT-401, a potentially transformative in vivo gene editing medicine designed to treat hyperlipidemia, toward the clinic,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We are highly encouraged by our recent preclinical safety and efficacy data, including emerging data from our GLP toxicology study, as well as data demonstrating EDIT-401’s ability to reduce multiple independent risk factors for atherosclerotic cardiovascular disease, including LDL-C, Lp(a), and ApoB, in non-human primates. Based on these data, we believe EDIT-401 has a potential best-in-class profile as a one-time treatment for hyperlipidemia, and we remain on track to initiate a first-in-human study with early human proof-of-concept data by year end.” Upcoming Data Presentations American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, May 11-15 Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C Pharmacokinetics and Pharmacodynamics of EDIT-401(mu), an In Vivo Gene Editing Therapy for Lowering LDL-C in Mice In vivo CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model TIDES USA 2025: Oligonucleotide & Peptide Therapeutics, May 11-14 Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease 94th European Atherosclerosis Society (EAS) Congress, May 24-27 A Transformative In Vivo CRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human Primates 2026 National Lipid Association (NLA) Sessions, June 11-14 A Transformative In Vivo CRISPR Gene Editing Medicine Leads to Upregulation of LDLR and Robust Reduction of Two Independent ASCVD Risk Factors, LDL-C and Lp(a), in Preclinical Studies EDIT-401 Editas continues to advance preclinical studies for its lead in vivo development candidate, EDIT-401, including the Good Laboratory Practice (GLP) toxicology study in non-human primates to support advancement into a first-in-human clinical trial. The Company is preparing to initiate a first-in-human clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) later this year, and expects to have early human proof-of-concept data by the end of 2026. Editas plans to complete enrolling the dose-finding portion of the first-in-human clinical trial of EDIT-401 with topline data results available in 2027. Intellectual Property On March 26, the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (PTAB’s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents exclusively licensed to Editas Medicine for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology, and Harvard University (collectively, Broad). This action by the PTAB is its third favorable decision determining that Broad was the first to invent the use of CRISPR/Cas9 for gene editing in eukaryotic cells, including human cells. CVC retains the right to appeal the decision. Upcoming Events Editas Medicine plans to participate in the following investor event: 2026 Jefferies Global Healthcare Conference Format: Presentation Date: June 4, 2026 Time: 4:20 p.m. ET New York, NY To access a live webcast of the investor presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event. First Quarter 2026 Financial Results Cash and cash equivalents as of March 31, 2026, were $123.6 million compared to $146.6 million as of December 31, 2025. The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2027. First Quarter 2026 For the three months ended March 31, 2026, net loss attributable to common stockholders was $25.0 million, or $0.26 per share, compared to net loss of $76.1 million, or $0.92 per share, for the same period in 2025. Collaboration and other research and development revenues decreased to $2.8 million for the three months ended March 31, 2026, compared to $4.7 million for the same period in 2025. The decrease is primarily attributable to the recognition of the remaining deferred revenue upon conclusion of a collaboration agreement with a strategic partner in 2025. Research and development expenses decreased by $9.0 million to $17.6 million for the three months ended March 31, 2026, compared to $26.6 million for the same period in 2025. The decrease is primarily related to reduced headcount (the “Reduction”) and decreased clinical and manufacturing costs related to discontinuation of the clinical development of the Company’s reni-cel program (the “Discontinuation”) initiated in December 2024 and ongoing throughout 2025, partially offset by costs attributable to in vivo research and discovery in 2026 and increased sublicense and license fees. General and administrative expenses decreased by $3.1 million to $10.2 million for the three months ended March 31, 2026, compared to $13.4 million for the same period in 2025. The decrease is primarily attributable to a reduction in employee-related expenses related to the Reduction, as well as reduced professional services in connection with the discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024 and ongoing throughout 2025. For the three months ended March 31, 2026, the Company recorded no restructuring and impairment charges compared to $40.9 million for the same period in 2025. The restructuring and impairment charges for the three months ended March 31, 2025 were primarily attributable to reni-cel related contract costs, accelerated expense recognized due to changes in useful life estimates for leasehold improvements, software, and a right-of-use asset, and impairment charges related to the sale of certain assets, resulting from the actions associated with the Discontinuation and the Reduction. About Heterozygous Familial Hypercholesterolemia (HeFH) Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population. About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to initiate a first-in-human clinical trial of EDIT-401 later this year, achieve early human proof-of-concept data for EDIT-401 by year-end 2026, and complete enrolling the dose-finding portion of the EDIT-401 clinical trial with topline data results available in 2027; the timing for the Company’s receipt and presentation of data from its preclinical studies; the potential of, and expectations for, EDIT-401 and the Company’s other future in vivo product candidates; the timing or likelihood of regulatory submissions and approvals; and the Company’s expectations regarding its cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated; and that the Company will not be able to raise funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. CONTACT: Investor and Media Contacts: [email protected] [email protected]

A month has gone by since the last earnings report for Black Diamond (BDTX). Shares have added about 19.3% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Black Diamond due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Black Diamond Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late. Black Diamond Posts Narrower Q4 Loss Black Diamond did not generate any revenue in the fourth quarter of 2025, consistent with the prior-year period. The company posted an adjusted net loss per share of 14 cents per share, slightly narrower than a loss of 28 cents in the year-ago quarter, reflecting modest improvement in overall profitability. Operating performance during the quarter benefited significantly from lower expenses following restructuring efforts and a sharper focus on core assets. Research and development (R&D) expenses fell nearly 49% to $6.3 million, while general and administrative (G&A) expenses declined about 34% to $4.0 million. These reductions more than offset a $7.3 million non-cash impairment charge related to right-of-use assets and property and equipment. As a result, total operating expenses decreased to $17.6 million from $18.3 million in the prior-year quarter. Other income provided a modest tailwind, with interest income increasing to $1.2 million from $0.6 million, contributing to total other income of $2.5 million versus $2.3 million a year earlier. The company also delivered a slight earnings surprise, driven by improved cost control and a narrower loss base. Although no revenue was recorded in the quarter, full-year FY2025 results included $70 million in license revenue from a strategic agreement with Servier. This upfront payment supported a shift to full-year profitability and strengthened cash flows. Black Diamond continues to streamline its operations and prioritize its lead asset, silevertinib, including out-licensing non-core programs. Management highlighted encouraging early clinical data in EGFR-mutant NSCLC and GBM, with strong response rates observed in phase II studies. Upcoming catalysts include additional NSCLC data readouts and the initiation of a randomized phase II GBM trial in 2026. The company is also exploring partnerships to support later-stage development. The balance sheet remains a key strength, with cash, cash equivalents, and investments rising to $128.7 million at year-end 2025, up more than 30% year over year. Management expects this liquidity to fund operations into the second half of 2028. Notably, full-year operating cash flow turned positive at $29.6 million, compared to a significant outflow in FY2024, driven by the Servier upfront payment, reduced expenses, and higher interest income. In the past month, investors have witnessed a flat trend in estimates revision. Currently, Black Diamond has a subpar Growth Score of D, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Black Diamond has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Black Diamond is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Editas Medicine (EDIT), a stock from the same industry, has gained 37.8%. The company reported its results for the quarter ended December 2025 more than a month ago. Editas reported revenues of $24.74 million in the last reported quarter, representing a year-over-year change of -19.2%. EPS of -$0.06 for the same period compares with -$0.55 a year ago. For the current quarter, Editas is expected to post a loss of $0.30 per share, indicating a change of +30.2% from the year-ago quarter. The Zacks Consensus Estimate has changed -29.2% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Editas. Also, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Black Diamond Therapeutics, Inc. (BDTX) : Free Stock Analysis Report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 3.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. Editasreported a loss of 6 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 55 cents per share in the year-ago quarter. The comprehensive beat was mainly due to lower operating expenses. Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, were $24.7 million in the reported quarter, down 19% from the year-ago quarter’s figure. The reported figure, however, comprehensively beat the Zacks Consensus Estimate of $7 million. The year-over-year decrease is primarily due to the recognition of revenues related to milestones achieved under EDIT’s collaboration agreement with Bristol Myers in the year-ago quarter. In the fourth quarter of 2025, R&D expenses decreased 44% to $27.4 million compared with $48.6 million reported in the year-ago period. The decline in R&D expenses is primarily due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by in vivo research and discovery costs. General and administrative expenses were $11.4 million in the reported quarter, down 31% year over year, due to a decrease in employee-related expenses because of reduced workforce and reduced professional service expenses following the abandonment of the reni-cel program. Restructuring and impairment charges fell by $18.5 million to a $6.3 million benefit in the fourth quarter from $12.2 million a year earlier, mainly due to favorable adjustments to previously estimated contract costs tied to the discontinuation of the reni-cel program. Editas had cash, cash equivalents and investments worth $146.6 million as of Dec. 31, 2025, down from $165.6 million as of Sept. 30, 2025. The company expects that its existing cash position will fund operating and capital needs into the third quarter of 2027. In 2025, Editas recorded total revenues of $40.5 million, which beat the Zacks Consensus Estimate of $21.4 million. The recorded figure increased 25% from the $32.3 million reported in 2024. EDIT reported a loss per share of $1.80 in 2025, narrower than the Zacks Consensus Estimate of a loss of $2.03 per share. In 2024, the company reported a loss per share of $2.88. In the past month, investors have witnessed a upward trend in estimates revision. The consensus estimate has shifted -29.21% due to these changes. Currently, Editas has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock has a grade of F on the value side, putting it in the fifth quintile for value investors. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Editas is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Puma Biotech (PBYI), a stock from the same industry, has gained 15%. The company reported its results for the quarter ended December 2025 more than a month ago. Puma Biotech reported revenues of $75.5 million in the last reported quarter, representing a year-over-year change of +27.7%. EPS of $0.29 for the same period compares with $0.43 a year ago. For the current quarter, Puma Biotech is expected to post a loss of $0.13 per share, indicating a change of -230% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Puma Biotech. Also, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates. “We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We continue to advance our lead in vivo development candidate, EDIT-401, an experimental, potential best-in-class, one-time therapy, which demonstrated significantly reduced mean LDL cholesterol levels of over 90 percent in preclinical studies. With cash runway into the third quarter of 2027, we are in a strong position to drive EDIT-401 toward upcoming milestones and look forward to submitting an IND/CTA by mid-2026 and initiating our first-in-human trial of EDIT-401 in patients living with heterozygous familial hypercholesterolemia (HeFH) later this year.” Recent Achievements and Upcoming Milestones Editas continues to advance its lead in vivo development candidate, EDIT-401, which has demonstrated the potential to reduce mean LDL cholesterol levels by more than 90 percent in non-human primates, and will present additional preclinical data by mid-2026. The Company remains on track to submit an IND/CTA for EDIT-401 by mid-2026. Editas is preparing to initiate a first-in-human clinical trial in patients with HeFH later this year, and the Company is on track to achieve early human proof-of-concept data by the end of 2026. Editas plans to complete enrolling the dose-finding portion of the first-in-human clinical trial with topline data results available in 2027. Upcoming Events Editas Medicine plans to participate in the following investor event: Barclays 28th Annual Global Healthcare Conference Format: Fireside Chat Date: March 12, 2026 Time: 8:30 a.m. ET Miami Beach, FL To access a live webcast of the investor presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event. Fourth Quarter and Full Year 2025 Financial Results Cash and cash equivalents as of December 31, 2025, were $146.6 million compared to $269.9 million as of December 31, 2024. The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2027. Fourth Quarter 2025 For the three months ended December 31, 2025, net loss attributable to common stockholders was $5.6 million, or $0.06 per share, compared to net loss of $45.4 million, or $0.55 per share, for the same period in 2024. Collaboration and other research and development revenues decreased to $24.7 million for the three months ended December 31, 2025, compared to $30.6 million for the same period in 2024. The decrease is primarily attributable to the recognition of revenue related to milestones achieved under the Company’s collaboration agreement with BMS in the fourth quarter of 2024. Research and development expenses decreased by $21.2 million to $27.4 million for the three months ended December 31, 2025, compared to $48.6 million for the same period in 2024. The decrease is primarily related to reduced clinical and manufacturing costs related to discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024, partially offset by costs attributable to in vivo research and discovery. General and administrative expenses decreased by $5.0 million to $11.4 million for the three months ended December 31, 2025, compared to $16.4 million for the same period in 2024. The decrease is primarily attributable to a reduction in employee-related expenses related to reduced headcount associated with the reduction in workforce, as well as reduced professional services in connection with the discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024. Restructuring and impairment charges decreased by $18.5 million to a $6.3 million benefit for the three months ended December 31, 2025, compared to $12.2 million for the same period in 2024. The decrease is primarily attributable to favorable adjustments to prior estimated costs for contracts associated with the discontinuation of the clinical development of the Company’s reni-cel program upon finalization of contract costs. Full Year 2025 For the full year 2025, net loss attributable to common stockholders was $160.1 million, or $1.80 per share, compared to net loss of $237.1 million, or $2.88 per share, for the same period in 2024. Collaboration and other research and development revenues increased to $40.5 million for 2025, compared to $32.3 million for the same period in 2024. The increase was attributable to recognition of the remaining deferred revenue upon the conclusion of a collaboration agreement with a strategic partner, as well as recognition of revenue related to a milestone achieved in 2025 under our collaboration with BMS. Research and development expenses decreased by $109.2 million to $90.0 million for 2025, compared to $199.2 million for the same period in 2024. The decrease was primarily attributable to reduced clinical and manufacturing costs due to the discontinuation of the Company’s former reni-cel program, partially offset by costs attributable to in vivo research and discovery. General and administrative expenses decreased by $22.1 million to $49.9 million for 2025, compared to $72.0 million for the same period in 2024. The decrease was primarily related to reduced headcount associated with the workforce reduction and reduced professional services related to the discontinuation of the Company’s former reni-cel program. Restructuring and impairment charges increased by $48.4 million to $60.7 million for 2025, compared to $12.2 million for the same period in 2024. The increase was attributable actions associated with the discontinuation of the Company’s former reni-cel program and the associated workforce reduction. About Heterozygous Familial Hypercholesterolemia (HeFH) Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population. About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to achieve early human proof-of-concept data for EDIT-401 by year-end 2026 and complete enrolling the dose-finding portion of the EDIT-401 clinical trial with topline data results available in 2027; the timing for the Company’s receipt and presentation of data from its preclinical studies, including presenting additional preclinical data for EDIT-401 by mid-2026; the potential of, and expectations for, EDIT-401 and the Company’s other future in vivo product candidates; the timing or likelihood of regulatory submissions and approvals, including the timing of submission of an IND/CTA for EDIT-401 by mid-2026; and the Company’s expectations regarding its cash runway and the milestones that can be achieved with that cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated; and that the Company will not be able to raise funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. CONTACT: Investor and Media Contacts: [email protected] [email protected]

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 8.3% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Editasreported a loss of 28 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss of 75 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, were $7.5 million in the reported quarter, up significantly from the year-ago quarter’s figure. The reported figure comprehensively beat the Zacks Consensus Estimate of $2 million. The increase is primarily driven by the recognition of revenues related to a milestone achievement under a collaboration agreement with Bristol Myers. In the third quarter of 2025, R&D expenses decreased 58% to $19.8 million compared with $47.6 million reported in the year-ago period. The downtick in R&D expenses is mainly due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by costs of in vivo research and discovery. General and administrative expenses were $12.3 million in the reported quarter, down 32% year over year, due to a decrease in employee-related expenses resulting from a reduced workforce following the abandonment of the reni-cel program. EDIT did not record any restructuring and impairment charges in the reported quarter. Editas had cash, cash equivalents and investments worth $165.6 million as of Sept. 30, 2025, down from $178.5 million as of June 30, 2025. The company expects that its existing cash position, together with $17.3 million in ATM proceeds raised after Sept. 30, 2025, and retained payments from its Vertex license agreement, will fund operating and capital needs into the third quarter of 2027. In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -42.11% due to these changes. Currently, Editas has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the lowest quintile for value investors. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Editas belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Beam Therapeutics Inc. (BEAM), has gained 17.8% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025. Beam Therapeutics reported revenues of $9.7 million in the last reported quarter, representing a year-over-year change of -32%. EPS of -$1.10 for the same period compares with -$1.17 a year ago. For the current quarter, Beam Therapeutics is expected to post a loss of $1.13 per share, indicating a change of -3.7% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Beam Therapeutics. Also, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research